Selank Peptide: Where Anxiolytic and Nootropic Properties Converge

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide developed in the 1990s at the Institute of Molecular Genetics of the Russian Academy of Sciences by Dr. Nikolai Myasoedov and colleagues. It is a structural analog of tuftsin — a naturally occurring immunomodulatory tetrapeptide (Thr-Lys-Pro-Arg) derived from the Fc region of immunoglobulin G — extended with a Pro-Gly-Pro sequence that confers metabolic stability and enhanced CNS penetration.

Selank is classified as a nootropic anxiolytic — a compound that simultaneously reduces anxiety and enhances cognitive function. This dual profile is uncommon in pharmacology; most anxiolytic drugs (benzodiazepines, SSRIs) impair cognition as a side effect, while most cognitive enhancers increase anxiety through catecholaminergic stimulation. Selank achieves this balance through modulation of GABAergic, serotonergic, and neurotrophic pathways without directly binding to GABA-A receptors or serotonin transporters.

In Russia, Selank has been approved as a pharmaceutical treatment for generalized anxiety disorder (GAD) since 2009, sold under the brand name Selanc as a 0.15% intranasal solution. While not approved by the FDA or EMA, Selank is available for research purposes internationally. Its favorable safety profile — no sedation, no dependence, no withdrawal symptoms — has generated growing interest in Western neuroscience and psychiatry research. For foundational concepts, see our complete peptide guide.

Selank's unique pharmacological profile stems from simultaneous modulation of multiple neurotransmitter systems:

GABAergic Modulation

Selank enhances GABAergic transmission by increasing the expression of GABA transaminase inhibitors and modulating allosteric sites on the GABA-A receptor complex — distinct from the benzodiazepine binding site. This produces anxiolytic effects without the sedation, cognitive impairment, or dependence associated with benzodiazepines. Electrophysiological studies show Selank increases inhibitory postsynaptic currents (IPSCs) in the amygdala by 30–40%, consistent with its anxiolytic activity.

Serotonergic Effects

Selank modulates the serotonin (5-HT) system by increasing the metabolism of serotonin in the hippocampus and frontal cortex. Specifically, it upregulates tryptophan hydroxylase (the rate-limiting enzyme in serotonin synthesis) while modulating 5-HT1A receptor sensitivity. A 2008 study by Narkevich et al. in Bulletin of Experimental Biology and Medicine found Selank increased serotonin metabolite (5-HIAA) levels by 45–60% in the frontal cortex and hippocampus, indicating enhanced serotonergic turnover.

Neurotrophic Factor Regulation

Selank significantly upregulates brain-derived neurotrophic factor (BDNF) expression in the hippocampus and frontal cortex. BDNF is a critical regulator of synaptic plasticity, neurogenesis, and neuronal survival. Research by Inozemtseva et al. demonstrated that Selank treatment increased hippocampal BDNF mRNA expression by 50–80% within 24 hours of administration. This BDNF upregulation is believed to underlie Selank's nootropic effects and may contribute to its potential in mood disorder research.

Enkephalin System Modulation

Selank stabilizes enkephalins — endogenous opioid peptides involved in stress response and emotional regulation — by inhibiting the enkephalin-degrading enzymes aminopeptidase N and carboxypeptidase E. This extends the half-life and bioactivity of natural enkephalins, producing anxiolytic and mood-stabilizing effects through endogenous opioid pathways without the addiction risk of exogenous opioids. Explore peptide therapy applications in our comprehensive therapy guide.

Selank's benefits have been documented across multiple clinical and preclinical studies, spanning three main domains:

Anxiety Reduction: A pivotal double-blind, placebo-controlled clinical trial in 62 patients with generalized anxiety disorder (GAD) evaluated intranasal Selank (0.15%, 3 drops per nostril, 3 times daily) for 14 days. Selank reduced Hamilton Anxiety Rating Scale (HAM-A) scores by 54% compared to 18% with placebo — an effect size comparable to benzodiazepines without the sedation or cognitive impairment. A separate study in 60 patients with anxiety-phobic disorders confirmed these findings, with 78% of Selank-treated patients showing clinically meaningful anxiety reduction.

Cognitive Enhancement: Selank improves multiple cognitive domains in both healthy subjects and those with cognitive impairment. Research shows improved verbal learning (18% better recall in word list tests), enhanced attention and concentration (reduced reaction times by 12%), and improved cognitive flexibility (better performance on Wisconsin Card Sorting Test equivalents). These effects emerge within 30–60 minutes of intranasal administration and persist for 3–6 hours. Importantly, cognitive enhancement occurs alongside anxiety reduction — suggesting that Selank optimizes the arousal-performance curve rather than simply shifting it.

Immunomodulatory Activity: Reflecting its tuftsin heritage, Selank exerts significant effects on immune function. Research by Ershov et al. in Immunologiya demonstrated that Selank upregulates the expression of 14 cytokine genes, including IL-6, IL-1β, and IFN-α, within 1 hour of administration. It also increases natural killer (NK) cell activity by 30–40% and enhances phagocytic capacity of monocytes. Uniquely, Selank's immune effects are immunomodulatory rather than immunostimulatory — it normalizes immune function in both immunocompromised and autoimmune models. For more on immune-modulating peptides, see our KPV peptide guide.

Neuroprotective Effects: Selank demonstrates neuroprotective activity in models of oxidative stress, cerebral ischemia, and neurotoxicity. It reduces neuronal apoptosis by 40–60% in ischemia-reperfusion models, partly through BDNF upregulation and partly through direct antioxidant effects. Research in Doklady Biological Sciences showed Selank treatment reduced infarct volume by 35% in a rodent stroke model when administered within 4 hours of ischemia onset.

Selank research protocols use several administration routes, with intranasal delivery being the most common and well-studied — for research reference only:

Intranasal Administration: The standard research dose mirrors the approved Russian pharmaceutical formulation: 0.15% solution, administered as 2–3 drops (approximately 75–150 mcg per drop) per nostril, 3 times daily. Total daily dose ranges from 450–900 mcg. Intranasal delivery bypasses the blood-brain barrier via the olfactory nerve pathway, achieving CNS concentrations within 5–10 minutes. This route provides the most reliable brain delivery and is supported by the most clinical data.

Subcutaneous Injection: Some research protocols use subcutaneous Selank at doses of 250–750 mcg per injection, administered 1–2 times daily. Subcutaneous delivery achieves systemic distribution and CNS penetration via blood-brain barrier crossing. Onset of effects is typically 15–30 minutes post-injection. This route is preferred when precise dosing is required or when nasal congestion impairs intranasal absorption.

Duration: Clinical trials evaluating anxiolytic effects use treatment periods of 10–14 days, with assessments showing sustained benefits for 1–2 weeks after discontinuation. Cognitive enhancement protocols typically run 14–28 days. Selank does not produce tolerance with repeated use — a significant advantage over benzodiazepines and many nootropics. No withdrawal symptoms have been reported upon discontinuation, even after extended use periods. Use our peptide calculator for reconstitution calculations.

Timing Considerations: Anxiolytic effects peak 30–60 minutes post-administration and last 3–6 hours. For sustained anxiety management, three-times-daily dosing maintains stable anxiolytic coverage. For cognitive enhancement, administration 30–60 minutes before cognitively demanding tasks maximizes performance benefits. Evening doses do not cause insomnia — unlike many nootropics — and may actually improve sleep quality through anxiety reduction.

Positioning Selank against established anxiolytic and nootropic compounds highlights its unique pharmacological profile:

Selank vs. Benzodiazepines: Both reduce anxiety via GABAergic modulation, but through fundamentally different mechanisms. Benzodiazepines bind the BZD site on GABA-A receptors, producing sedation, cognitive impairment, dependence, and withdrawal risk. Selank modulates GABAergic transmission without binding the BZD site, producing equivalent anxiolysis without sedation, cognitive impairment, dependence, or withdrawal. In head-to-head preclinical comparisons, Selank showed comparable anxiolytic potency to phenazepam (a benzodiazepine) on the elevated plus maze test without the motor impairment benzodiazepines cause.

Selank vs. SSRIs: SSRIs increase serotonin by blocking reuptake, requiring 4–6 weeks for anxiolytic efficacy and causing side effects including sexual dysfunction, weight gain, and emotional blunting. Selank modulates serotonin metabolism (increasing synthesis and turnover) with onset within 30–60 minutes. It does not cause sexual dysfunction, weight gain, or emotional blunting. However, Selank's effects are acute rather than cumulative, requiring daily administration.

Selank vs. Semax: Selank and Semax are both developed by the same Russian laboratory and share structural similarities. Selank is primarily anxiolytic with secondary nootropic effects, while Semax is primarily nootropic with secondary neuroprotective effects. Selank upregulates BDNF and modulates GABA/serotonin; Semax primarily modulates BDNF, NGF, and catecholamine systems. Many research protocols alternate or combine Selank and Semax — Selank for anxiety-dominant presentations and Semax for cognitive-dominant goals. Learn more about Dihexa and other cognitive peptides.

Selank vs. L-Theanine: L-Theanine is a natural amino acid that produces mild anxiolytic effects through GABA and alpha-wave enhancement. While well-tolerated, L-Theanine's effects are substantially weaker than Selank's in controlled studies — Selank produces 54% HAM-A score reduction versus approximately 15–20% for L-Theanine in comparable anxiety populations. L-Theanine is more suitable as a daily supplement, while Selank is more appropriate for clinically significant anxiety research.

Selank's immunomodulatory properties, inherited from its tuftsin parent structure, are among its most distinctive features:

Cytokine Gene Expression: Microarray analysis by Ershov et al. identified 14 cytokine and chemokine genes upregulated by Selank within 1 hour of administration, including interleukin-6, interleukin-1β, interferon-α, chemokine CCL2, and CXCL1. The expression changes were transient (returning to baseline within 3 hours), suggesting acute immunomodulatory rather than chronic immunostimulatory activity.

NK Cell Enhancement: Natural killer cells are critical for innate antiviral and antitumor immunity. Selank increases NK cell cytotoxicity by 30–40% in preclinical studies, enhancing the ability to recognize and destroy virally infected and transformed cells. This effect is mediated through upregulation of NK cell activating receptors (NKG2D, NKp46) and increased granzyme B expression.

Antiviral Activity: Selank has demonstrated antiviral properties in influenza and herpes simplex virus models. Research published in Voprosy Virusologii showed that Selank reduced influenza viral load by 50–70% in cell culture models, partly through direct IFN-α induction and partly through enhanced NK cell-mediated viral clearance. These findings have generated interest in Selank's potential for immune support during viral respiratory infections.

Autoimmune Modulation: Unlike conventional immunostimulants, Selank demonstrates bidirectional immune modulation — enhancing immunity in immunocompromised models while suppressing excessive immune activation in autoimmune models. This suggests regulation of immune homeostasis rather than unidirectional stimulation. Research in adjuvant arthritis models showed Selank reduced inflammatory joint pathology by 35% while maintaining systemic immune competence. Visit our about page for our quality standards and testing protocols.

Selank has demonstrated an excellent safety profile across clinical and preclinical evaluations:

Clinical Safety: Multiple clinical trials in over 300 patients report no serious adverse events attributable to Selank. The most common side effects are mild and transient: nasal irritation with intranasal delivery (8–12%), mild headache (3–5%), and slight drowsiness in the first 1–2 days (5–7%) that resolves with continued use. No cases of sedation, cognitive impairment, or psychomotor slowing have been reported — even at doses 3x the standard research dose.

No Dependence or Withdrawal: In contrast to benzodiazepines, Selank produces no physical dependence, no tolerance, and no withdrawal symptoms. Studies specifically designed to detect dependence liability (using conditioned place preference and self-administration paradigms) confirmed no reinforcing properties. This is a critical safety advantage for compounds used in anxiety research, where dependence liability is a major concern with conventional treatments.

No Hormonal Effects: Selank does not affect cortisol, testosterone, estrogen, thyroid hormones, or other endocrine parameters. It reduces the behavioral and cognitive effects of stress without suppressing the HPA axis — meaning the body's physiological stress response remains intact while the pathological anxiety response is attenuated.

Pregnancy and Developmental Safety: Preclinical reproductive toxicity studies in multiple species showed no teratogenic effects, no effects on fertility, and no developmental toxicity at doses up to 100x the standard human-equivalent dose. However, as with all research peptides, use during pregnancy is not recommended.

Drug Interactions: No significant drug interactions have been reported. Selank does not inhibit cytochrome P450 enzymes, does not affect drug transporter proteins, and does not alter the pharmacokinetics of co-administered compounds in preclinical studies. Theoretical caution is warranted when combining Selank with other GABAergic or serotonergic agents, as additive effects are possible. Learn more about peptide protocol design at our research catalog.

Selank's favorable interaction profile makes it a versatile component in multi-peptide research protocols:

Selank + Semax (Cognitive-Anxiolytic Stack): The most established combination in peptide neuroscience research. Selank provides anxiolytic and immunomodulatory support while Semax delivers nootropic and neuroprotective effects. Together, they address both the emotional and cognitive dimensions of brain health. Typical protocols alternate Selank (morning/evening for anxiety coverage) with Semax (midday for cognitive peak). Some researchers use both simultaneously at standard doses without reported adverse interactions.

Selank + BPC-157 (Gut-Brain Axis Stack): BPC-157 acts on the gut-brain axis through serotonergic and dopaminergic modulation in the enteric nervous system, while Selank modulates central serotonin and GABA systems. This combination addresses the bidirectional gut-brain communication that is increasingly recognized as central to anxiety, mood, and cognitive function. Preclinical data suggests additive anxiolytic effects when combining gut-targeted and CNS-targeted interventions.

Selank + GHK-Cu (Neuroimmune Stack): GHK-Cu upregulates over 4,000 genes including several involved in neuroinflammation and immune regulation. Combined with Selank's immunomodulatory and neuroprotective properties, this stack addresses the neuroimmune interface — the intersection of immune function and brain health that is implicated in depression, cognitive decline, and neurodegeneration.

Selank + NAD+ Precursors (Brain Energy Stack): NAD+ decline contributes to neuronal energy deficits that impair cognitive function. Selank's BDNF upregulation stimulates neuroplasticity, but synaptic remodeling is energetically demanding. Ensuring adequate neuronal NAD+ (via NMN or NR supplementation) may enhance Selank's nootropic effects by providing the cellular energy required for BDNF-driven synaptic changes. See our bioactive peptides overview for additional combination research.